Tiffet Olivier, Kaczmarek David, Chambonnière Marie Laure, Guillan Thomas, Baccot Sylviane, Prévot Nathalie, Bageacu Sherban, Bourgeois Eric, Cassagnau Elisabeth, Lehur Paul Antoine, Dubois Francis
Department of General Surgery, University Hospital of Saint Etienne, Saint Etienne, France.
Dis Colon Rectum. 2007 Jul;50(7):962-70. doi: 10.1007/s10350-007-0236-3.
This study was designed to assess the feasibility of a combined colorimetric and radioisotopic technique in the detection of the sentinel lymph node in colorectal cancer.
This prospective dual-center study included 64 patients. Using endoscopy on D0, a radiolabeled colloid was injected into the peritumoral submucosa, followed by a lymphoscintigraphy. Intraoperatively, on D1, lymphatic mapping was performed by using a visual method and radioguided detection after subserosal peritumoral injection of patent blue. Twenty-nine patients were injected only with the patent blue, 18 patients only with the radioactive tracer, and the other 17 patients benefited from both techniques.
The detection rate was 92 percent. The average number of sentinel nodes harvested was 2.8. Twenty-four of 59 patients were pN+ (40 percent) and in 12 cases the sentinel lymph node was histologically negative, although there was a positive nonsentinel node (false-negative rate, 50 percent). The false-negative rate for the combined, radioisotopic, and colorimetric techniques were 63, 60, and 36 percent, respectively. In four patients, the sentinel node was the only metastatic site (4/24, 17 percent), and in two of these four patients, the sentinel lymph node presented with micrometastases (<2 mm). The radioisotopic technique allowed us to highlight a lateral drainage of two rectal cancers (2/13, 15 percent). The concordance between the blue and radioactive sentinel nodes was 43 percent.
The addition of a radioisotopic method using submucosal injection does not improve the false-negative rate. The sentinel lymph node technique in colorectal cancer is feasible, although the false-negative rate is such that the technique should still be considered as experimental.
本研究旨在评估比色法和放射性同位素技术联合用于检测结直肠癌前哨淋巴结的可行性。
这项前瞻性双中心研究纳入了64例患者。在第0天进行内镜检查时,将放射性标记的胶体注射到肿瘤周围的黏膜下层,随后进行淋巴闪烁显像。在第1天手术中,在肿瘤周围浆膜下注射专利蓝后,采用视觉方法和放射性引导检测进行淋巴绘图。29例患者仅注射了专利蓝,18例患者仅注射了放射性示踪剂,另外17例患者同时采用了这两种技术。
检测率为92%。收获的前哨淋巴结平均数量为2.8个。59例患者中有24例为pN+(40%),12例患者的前哨淋巴结组织学检查为阴性,尽管存在非前哨淋巴结阳性(假阴性率为50%)。联合技术、放射性同位素技术和比色法的假阴性率分别为63%、60%和36%。在4例患者中,前哨淋巴结是唯一的转移部位(4/24,17%),在这4例患者中的2例中,前哨淋巴结出现微转移(<2 mm)。放射性同位素技术使我们能够发现2例直肠癌的侧方引流(2/13,15%)。蓝色和放射性前哨淋巴结之间的一致性为43%。
采用黏膜下注射的放射性同位素方法并不能降低假阴性率。结直肠癌的前哨淋巴结技术是可行的,尽管假阴性率较高,该技术仍应被视为实验性技术。